Tehran (IP) - Regarding the vaccine and medicinal drug for coronavirus and its mass-production the Iranian Ministry of Health and Medical Education spokesperson stated that Iranian researchers have developed the technology to make one of the bio-similar monoclonal antibody drugs.

Iran Press/Iran news: In an exclusive interview with Iran Press News Agency, the Spokesman for the Iranian Ministry of Health and Medical Education Kianoush Jahanpour said that there have been reports from China that this drug may reduce some inflammatory reactions in some COVID-19 patients and improve the condition. A clinical trial has been conducted to evaluate the efficacy of this drug and its first case was performed in a hospital in Isfahan on a 50-year-old woman.

Jahanpour added, "There have been reports that improvements have been made after 24 and 48 hours but cannot be judged at this time, and this drug should be tested on a larger number and if it proves to be a partial proof of its mass production in the first place."

Iranian spokesman for the Ministry of Health and Medical Education said, however, that the drug is not the subject of direct COVID-19 treatment, but rather the reduction of complications for specific cases.

"Of course, other drugs have been introduced in the early stages of illness, some of which can be manufactured in the country and others have been manufactured before," Jahanpour said.


Read More:

Latest statistics of Coronavirus tolls in Iran

US closes Iran access to resources needed to provide Coronavirus medicine

Government is fully ready and working to fight the Coronavirus